Health Catalyst Inc
$ 2.52
4.13%
29 Dec - close price
- Market Cap 171,169,000 USD
- Current Price $ 2.52
- High / Low $ 2.54 / 2.39
- Stock P/E N/A
- Book Value 4.70
- EPS -1.58
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -0.31 %
- 52 Week High 7.65
- 52 Week Low 2.02
About
Health Catalyst, Inc. (HCAT) is a leading provider of innovative data and analytics solutions tailored for healthcare organizations, aimed at improving operational efficiencies and enhancing patient outcomes. Headquartered in South Jordan, Utah, the company employs a robust data platform coupled with advanced analytics to empower healthcare professionals with evidence-based decision-making tools across various settings. Positioned at the forefront of the burgeoning healthcare analytics market, Health Catalyst is uniquely equipped to meet the escalating demand for sophisticated analytical solutions in an industry increasingly focused on data-driven care delivery and improved quality outcomes.
Analyst Target Price
$3.94
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-11 | 2025-08-07 | 2025-05-07 | 2025-02-20 | 2024-11-06 | 2024-08-07 | 2024-05-09 | 2024-02-22 | 2023-10-27 | 2023-08-08 | 2023-05-09 | 2023-02-28 |
| Reported EPS | 0.06 | -0.59 | 0.01 | 0.04 | 0.07 | 0.12 | 0.05 | 0.02 | 0.03 | 0.05 | 0.05 | -0.05 |
| Estimated EPS | 0.0629 | 0.04 | 0.03 | 0.0764 | 0.1 | 0.08 | 0.03 | -0.0002 | -0.02 | -0.02 | -0.04 | -0.11 |
| Surprise | -0.0029 | -0.63 | -0.02 | -0.0364 | -0.03 | 0.04 | 0.02 | 0.0202 | 0.05 | 0.07 | 0.09 | 0.06 |
| Surprise Percentage | -4.6105% | -1575% | -66.6667% | -47.644% | -30% | 50% | 66.6667% | 10100% | 250% | 350% | 225% | 54.5455% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HCAT
2025-12-15 14:41:00
Several tech stocks, including HubSpot, nCino, Rapid7, and Health Catalyst, experienced a downturn due to increasing investor concern that significant AI investments might not yield sufficient profits, sparking fears of an "AI bubble." This sentiment was exacerbated by Broadcom's warning about thinner profit margins from increased AI system sales, leading to a broader market recalibration and a shift away from speculative tech investments. Despite the general selloff, nCino had recently authorized a new $100 million stock repurchase program, signaling management's confidence in the company.
2025-12-10 01:09:34
Health Catalyst's General Counsel, Benjamin Landry, sold 27,425 shares of HCAT stock on December 5th at an average price of $2.64, reducing his holdings by over 21%. Following the sale, he directly owns 100,000 shares. HCAT shares are currently trading around $2.61, and analysts maintain a "Hold" rating with an average price target of $4.36 despite recent target cuts.
2025-12-10 00:09:34
Health Catalyst (NASDAQ:HCAT) Director Julie Larson-Green sold 47,997 shares of the company's stock, valued at $128,151.99, reducing her ownership by 39.48%. The company's stock traded down 1.1% to $2.61, and analysts currently have a "Hold" rating with an average target price of $4.36. Health Catalyst reported slightly better-than-expected quarterly earnings but remains unprofitable.
2025-12-08 05:09:13
Health Catalyst's market capitalization has fallen to US$190 million after a 13% stock price decline, disappointing insiders who had invested US$895.1k at a higher average price. Despite these recent losses, the analysis of insider transactions suggests that Health Catalyst insiders remain optimistic about the company's future, with one director making a significant purchase above current prices. While insider ownership is not exceptionally high, the recent buying activity offers some confidence to investors looking at the company's prospects.
2025-12-07 07:10:19
Health Catalyst's stock has declined by 13%, causing insiders who invested US$895.1k at an average price of US$2.95 to now face a loss, with their investment currently worth US$789.1k. Despite this, a significant purchase by Director Mathew Arens at a higher price than the current stock value suggests insider optimism for the company's future. The company's insiders own 4.6% of the company, valued at US$8.8m, suggesting some alignment with shareholder interests.
2025-12-07 03:54:12
Health Catalyst, Inc.'s stock recently dropped by 13%, causing insiders who bought shares at an average of US$2.95 to experience losses, as their US$895.1k investment is now worth US$789.1k. The biggest insider purchase was made by Director Mathew Arens, who bought US$895k worth of shares at US$3.43 each, indicating prior optimism about the stock. Despite these recent losses, insider transactions suggest an expectation of a brighter future for Health Catalyst, though insider ownership remains relatively low at 4.6%.
